Diabetic needlestick injuries driving growth in sharps safety device spending
Thursday January 19 2017
An increasing number of needlestick injuries are being reported among diabetic patients who administer their own insulin and other medication at home, which is leading to a rise in spending on specialist sharps safety devices.
According to new figures from Transparency Market Research, more healthcare authorities across the globe will be significantly increasing their spending on needle safety devices for syringes and insulin pens between now and 2024 in order to reduce the risk of patients experiencing sharps injuries.
For individuals with either type 1 or type 2 diabetes, a needlestick injury sustained while injecting insulin can lead to the wrong dose being administered, which can have serious health consequences, even proving fatal in some cases.
What's more, if the needle has already been used or is broken and has been touched by somebody else, there is a risk of blood-borne viruses being passed from person to person. This increases the chance of potentially life-threatening diseases such as hepatitis C and HIV being spread, meaning best practice standards of sharps safety need to be followed at all times.
With this in mind, Transparency Market Research is predicting that spending on specialist devices to improve the safety of needles used in diabetes injector pens will increase among global healthcare authorities, who will then be able to advise their patients on using these instruments for improved sharps safety.
The report authors anticipate that North America, Europe, Asia and Latin America will lead this growth in the injection safety market, followed by the rest of the world.
It is hoped that by 2024, the number of needlestick injuries sustained each year by patients self-administering their diabetes medication will have fallen significantly, leading to fewer diagnoses of HIV and hepatitis C from the cross contamination of needles and blood as a result.